Education
About Us
Working with TipRanks
Follow Us
Bio-Path Holdings (BPTH)
OTHER OTC:BPTH
BPTH Stock Chart & Stats
$0.05
-$0.06(-5.61%)
At close: 4:00 PM EST
$0.05
-$0.06(-5.61%)
Day’s Range― - ―
52-Week Range$0.05 - $0.23
Previous CloseN/A
Volume216.71K
Average Volume (3M)24.92K
Market Cap
$635.86K
Enterprise Value$1.05M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$479.00K
Price to Earnings (P/E)―
Beta-1.20
Next Earnings
Mar 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding9,242,151
10 Day Avg. Volume24,655
30 Day Avg. Volume24,916
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)18.09
Price to Sales (P/S)0.00
P/FCF Ratio-0.26
Enterprise Value/Market Cap1.65
Enterprise Value/Revenue6.65
Enterprise Value/Gross Profit175.03
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformA proprietary delivery platform is a durable competitive asset in oligonucleotide therapeutics where delivery is a key technical barrier. DNAbilize can enable multiple programs, reduce trial failure risk from delivery issues, and improve partnerability and long-term program scalability.
Oncology-Focused Pipeline (AML)Concentrated focus on oncology, especially AML, targets structurally large unmet medical need and sustained commercial demand. Success in these indications creates durable value through high pricing potential, repeatable clinical pathways, and attractiveness to strategic partners or acquirers.
Low Absolute Debt BurdenMinimal nominal debt reduces interest and covenant pressures, preserving operational flexibility. With low interest burden the company can prioritize R&D or strategic transactions; this provides some runway advantage relative to highly leveraged peers despite other capital constraints.
Bears Say
No Product RevenueAbsence of product revenue means the business cannot self-fund development; persistent operating losses force reliance on external capital or partnerships. This structural lack of internal cash generation increases execution risk and makes long-term viability contingent on financing outcomes.
Severe Equity ErosionDramatic depletion of equity materially weakens the company’s capital cushion, reducing its ability to absorb further losses or fund trials internally. This elevates refinancing and dilution risk, constrains borrowing capacity, and increases the probability of distressed transactions over the coming months.
Financing & Listing RiskActive efforts to raise capital, hire new auditors, and engage bankers represent a structural shift toward funding-dependent restructuring. This heightens dilution, potential divestitures, and continuity/listing risk, creating strategic uncertainty that can delay R&D timelines and partner negotiations.
Bio-Path Holdings News
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.05 and its highest was $0.23 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $635.86K.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Mar 06, 2026 which is in 2 days.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on Nov 14, 2025. The company reported -$0.114 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.286.
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 9,242,151 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.114 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went up 12.791%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Technical Analysis
Ownership Overview
―
Insiders
2.73% Other Institutional Investors
97.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---